What it sells
AI software that estimates relative rejection risk of specific donor-recipient incompatibilities before transplant using existing workflow data; still in development.
Business model breakdown
Distribution: how it reaches customers
Land-and-expand in hospital networks, out-licensing to transplant-diagnostic companies, biopharma partnerships.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-13 | Strategic | $100K | — | thesaasnews.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.